The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Response pattern in 844 patients with infiltrating lobular carcinoma (ILC) of the breast after neoadjuvant chemotherapy.
Cristina Pirvulescu
No relevant relationships to disclose
Sibylle Loibl
No relevant relationships to disclose
Gunter Von Minckwitz
No relevant relationships to disclose
Christine Mau
No relevant relationships to disclose
Jens U. Blohmer
Honoraria - Roche; Sanofi
Serban Dan Costa
No relevant relationships to disclose
Holger Eidtmann
No relevant relationships to disclose
Peter A. Fasching
No relevant relationships to disclose
Bernd Gerber
Honoraria - AstraZeneca; GEK; Roche
Michael Untch
No relevant relationships to disclose